MM-PBSA Validation Study. Trent E. Balius Department of Applied Mathematics and Statistics AMS

Similar documents
MM-GBSA for Calculating Binding Affinity A rank-ordering study for the lead optimization of Fxa and COX-2 inhibitors

ONETEP PB/SA: Application to G-Quadruplex DNA Stability. Danny Cole

MD Simulation in Pose Refinement and Scoring Using AMBER Workflows

Optimization of a MM-PBSA/GBSA protocol for the prediction of binding free energy of Bcl-xL inhibitors 1. Abstract 2. Introduction

Molecular Interactions F14NMI. Lecture 4: worked answers to practice questions

Supplementary Information

To the best of my knowledge and as understood by the student in the Thesis/Dissertation Agreement, Publication Delay, and Certification/Disclaimer

Binding Free Energy Calculations for Lead Optimization: Assessment of Their Accuracy in an Industrial Drug Design Context

Enhancing Specificity in the Janus Kinases: A Study on the Thienopyridine. JAK2 Selective Mechanism Combined Molecular Dynamics Simulation

Scoring functions for of protein-ligand docking: New routes towards old goals

Docking. GBCB 5874: Problem Solving in GBCB

All-atom Molecular Mechanics. Trent E. Balius AMS 535 / CHE /27/2010

Supplementary Methods

Advanced in silico drug design

Progress of Compound Library Design Using In-silico Approach for Collaborative Drug Discovery

Bioengineering & Bioinformatics Summer Institute, Dept. Computational Biology, University of Pittsburgh, PGH, PA

The Molecular Dynamics Method

est Drive K20 GPUs! Experience The Acceleration Run Computational Chemistry Codes on Tesla K20 GPU today

User Guide for LeDock

A Large-Scale Test of Free-Energy Simulation Estimates of Protein-Ligand Binding Affinities.

Supporting Information

Dr. Sander B. Nabuurs. Computational Drug Discovery group Center for Molecular and Biomolecular Informatics Radboud University Medical Centre

Medical Research, Medicinal Chemistry, University of Leuven, Leuven, Belgium.

Hyeyoung Shin a, Tod A. Pascal ab, William A. Goddard III abc*, and Hyungjun Kim a* Korea

PROTEIN-PROTEIN DOCKING REFINEMENT USING RESTRAINT MOLECULAR DYNAMICS SIMULATIONS

SUPPLEMENTARY INFORMATION

Tailoring the Properties of Quadruplex Nucleobases for Biological and Nanomaterial Applications

arxiv: v1 [q-bio.qm] 31 Mar 2017

D3RGC2: free energy scoring by alchemical free energy implementation in SOMD

Why study protein dynamics?

Improving Protein Function Prediction with Molecular Dynamics Simulations. Dariya Glazer Russ Altman

The PhilOEsophy. There are only two fundamental molecular descriptors

New approaches to scoring function design for protein-ligand binding affinities. Richard A. Friesner Columbia University

Alchemical free energy calculations in OpenMM

Supporting information

Comparison of the Efficiency of the LIE and MM/GBSA Methods to Calculate LigandBinding Energies

Cooperativity and Specificity of Cys 2 His 2 Zinc Finger Protein-DNA Interactions: A Molecular Dynamics Simulation Study

Type II Kinase Inhibitors Show an Unexpected Inhibition Mode against Parkinson s Disease-Linked LRRK2 Mutant G2019S.

Structural insight into the binding of C60-derivatives with enoyl-pyruvate transferase from Helicobacter pylori

Molecular Simulation III

Supplementary information for cloud computing approaches for prediction of ligand binding poses and pathways

Structure Investigation of Fam20C, a Golgi Casein Kinase

Computational Modeling of Protein Kinase A and Comparison with Nuclear Magnetic Resonance Data

Lecture 12: Solvation Models: Molecular Mechanics Modeling of Hydration Effects

DOCKING TUTORIAL. A. The docking Workflow

Relative binding enthalpies from molecular dynamics simulations. using a direct method

Computational chemical biology to address non-traditional drug targets. John Karanicolas

Insights into Protein Protein Binding by Binding Free Energy Calculation and Free Energy Decomposition for the Ras Raf and Ras RalGDS Complexes

Molecular Mechanics, Dynamics & Docking

Principles of Drug Design

*Corresponding Author *K. F.: *T. H.:

Using Phase for Pharmacophore Modelling. 5th European Life Science Bootcamp March, 2017

Kd = koff/kon = [R][L]/[RL]

What is Protein-Ligand Docking?

Applications of Molecular Dynamics

DISCRETE TUTORIAL. Agustí Emperador. Institute for Research in Biomedicine, Barcelona APPLICATION OF DISCRETE TO FLEXIBLE PROTEIN-PROTEIN DOCKING:

Structure based drug design and LIE models for GPCRs

Conformational sampling of macrocycles in solution and in the solid state

A Deep Convolutional Neural Network for Bioactivity Prediction in Structure-based Drug Discovery

Homology modeling. Dinesh Gupta ICGEB, New Delhi 1/27/2010 5:59 PM

STRUCTURAL BIOINFORMATICS II. Spring 2018

Ligand Scout Tutorials

Biomolecules are dynamic no single structure is a perfect model

Challenges, Applications, and Recent Advances of Protein-Ligand Docking in Structure-Based Drug Design

Computational Analyses of Protein-Ligand Interactions

Statistical Mechanics for Proteins

5.1. Hardwares, Softwares and Web server used in Molecular modeling

Molecular Modeling -- Lecture 15 Surfaces and electrostatics

Principles of Drug Design

Mechanistic insight into inhibition of two-component system signaling

Biochemistry 675, Lecture 8 Electrostatic Interactions

Solvation and Macromolecular Structure. The structure and dynamics of biological macromolecules are strongly influenced by water:

Using AutoDock for Virtual Screening

Free energy simulations

SUPPLEMENTARY MATERIAL. Supplementary material and methods:

5323 Harry Hines Blvd., Dallas, TX Department of Chemistry and Biochemistry, University of California at San Diego,

Towards Physics-based Models for ADME/Tox. Tyler Day

Supplementary Figures

BioSolveIT. A Combinatorial Approach for Handling of Protonation and Tautomer Ambiguities in Docking Experiments

DOCK 3.7: How It Works and How to Tweak your Setup. Trent E. Balius Shoichet Lab Group Meeting 2014/10/31

Supporting Information. Copyright Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, 2006

Cheminformatics platform for drug discovery application

Protein-Ligand Docking

Chapter 6 Cyclic urea - a new central unit in bent-core compounds

Potential Energy (hyper)surface

Towards fast and accurate binding affinity. prediction with pmemdgti: an efficient. implementation of GPU-accelerated. Thermodynamic Integration

Development of Pharmacophore Model for Indeno[1,2-b]indoles as Human Protein Kinase CK2 Inhibitors and Database Mining

Joana Pereira Lamzin Group EMBL Hamburg, Germany. Small molecules How to identify and build them (with ARP/wARP)

Bioengineering 215. An Introduction to Molecular Dynamics for Biomolecules

The Schrödinger KNIME extensions

Goals. Structural Analysis of the EGR Family of Transcription Factors: Templates for Predicting Protein DNA Interactions

Predictive Molecular Simulation for Drug Discovery

Large-Scale DFT Calculations in Implicit Solvent A Case Study on the T4 Lysozyme L99A/M102Q Protein

Identifying Interaction Hot Spots with SuperStar

Specific Ion Solvtion in Ethylene Carbonate and Propylene Carbonate

BUDE. A General Purpose Molecular Docking Program Using OpenCL. Richard B Sessions

SUPPLEMENTARY FIGURES. Figure S1

Different conformations of the drugs within the virtual library of FDA approved drugs will be generated.

Retrieving hits through in silico screening and expert assessment M. N. Drwal a,b and R. Griffith a

Force Fields for Classical Molecular Dynamics simulations of Biomolecules. Emad Tajkhorshid

Transcription:

MM-PBSA Validation Study Trent. Balius Department of Applied Mathematics and Statistics AMS 535 11-26-2008

Overview MM-PBSA Introduction MD ensembles one snap-shots relaxed structures nrichment Computational vs. experimental activities ROC curves Validating MM-PBSA with virtual screening

Introduction to Molecular Mechanics Poisson Boltzmann Solvent Accessible Surface Area (MM-PBSA)

Thermodynamic cycle + gas ΔG bind rec ΔG hyd lig ΔG hyd com ΔG hyd wat ΔG bind +

MM-PBSA/GBSA quations G = G G G MM PBSA / GBSA polar nonpolar ΔG = MM such that = G + G bond complex PBSA / GBSA G polar G angle = α SA + β + G protein TS tors nonpolar G ligand vdw TS is calculated using quasi harmonic analysis normal mode analysis = + or by using the GB equation. + + + where the polar and the nonpolar terms are defined in the following way - is defined by solving the PB set of differential equations es

MM-PBSA/GBSA quations G = G G G MM PBSA / GBSA polar nonpolar ΔG = MM such that = G + G bond complex PBSA / GBSA G polar G angle = α SA + β + G protein TS tors nonpolar G ligand vdw TS is calculated using quasi harmonic analysis normal mode analysis = + or by using the GB equation. + + + where the polar and the nonpolar terms are defined in the following way - is defined by solving the PB set of differential equations es

Using Molecular Dynamics generated ensembles

Run 3 independent Simulations Protein-ligand Complex simulation Protein simulation Ligand simulation Time (ns)

Run 1 Simulations Protein-ligand Complex simulation remove ligand remove protien Protein simulation Ligand simulation Time (ns)

Metrics for Determining Good Agreement

Predictive Index (PI) prediction accuracy for ranking different inhibitors (i) -- experimental binding free energy P(i) -- calculated energy value of a ligand i, w ij --weighting term difference between the experimental values of the two ligands that are compared PI = 1, if always right PI = -1, if always wrong note that is a IC50 value and P is an energy score PI w C i, j i, j i j> i = = = i w j> i () i ( j) 1 1 0 i, j w C i, j if if i, j [ () i ( j) ] [ P() i P( j) ] [ () i ( j) ] [ P() i P( j) ] if [ P() i P( j) ] = 0 < > 0 0

Correlation Coefficient -- Probability Theory covariance variance expectation mean cov var [ X, Y ] = = [ ( X [ X ])( Y [ Y ])] [ XY ] [ X ] [ Y ] [ X ] = = [( [ ]) ] 2 X X [ X ] 2 2 ( [ X ]) [ X ] = n x p( x ) x = i= 1 1 n i n i= 1 x i i uniformly distributed D.P. Bertsekas, J.N. Tsitsiklis. Introduction to Probability, 2nd d.

Correlation Coefficient ρ ( X, Y ) R = S S xx = xy S yy cov var [ X, Y ] [ X ] var[ Y ] ˆ s = β1 s x y y y c =β 0 +β 1 x S s x xy = = n i= 1 ( x x)( y y), S = ( x x) i S xx n 1 i xx n i= 1 i estimated population standard deviation for uniform distribution 2 x A.C. Tamhane, D.D. Dunlop. Statistics and Data Analysis: From lementary to Intermediate D.P. Bertsekas, J.N. Tsitsiklis. Introduction to Probability, 2nd d.

Virtual Screening and Receiver Operating Characteristic (ROC) Curves

Virtual Screening (nrichment) total 100 % total 50 % positives negatives score sort throw away positives negatives positives 100 % positives 80 %

Computational Prediction vs. xperimental videnced has activity has little activity has predicted activity True Positive False Positive has little predicted activity False Negative True Negative

ROC curves ROC -- Receiver Operating Characteristic http://www.anaesthetist.com/mnm/stats/roc/findex.htm

ROC curves Active and inactive is not known Why not do the experiments on whole population? expensive takes time multiple levels of experiments (needs to comparing type of experiments e.g.. HTPS) Seed the population with know active compounds see how many bubble to the top.

Seed database ROC curves unknowns may have activity unknown known active Score Sort Keep Threshold Throw away

Paper Figures and Analysis

Paper Nomenclature MM-RDIL -- molecular mechanics energy function including distance dependent dielectric MM-PBSA -- single relaxed structure MD-PBSA -- molecular dynamics ensemble MD-PBSA* -- minimized staring point

Computational Details Force Fields (antechamber of Amber 7) small molecules AM1-BCC charges GAFF (failed in 10%) MAB* -- MAB (united atom) and GAFF Protein -- FF94 24 Å sphere of TIP3P water and neutralized by adding counter ions MD simulations -- Amber 6 for MD T = 300, Δt = 1.5fs, shake on equilibration: 150 ps snapshots every 5 ps for 50 ps 10 structures ensemble Minimization -- Related structure minimized for 1000 steps Journal of Medicinal Chemistry, 2005, Vol. 48, No. 12

Computational Details MM-PBSA calculations PB calculated using MAD program package Normal mode analysis -- mfebd module of MOLOC SA -- in-house program XSA Journal of Medicinal Chemistry, 2005, Vol. 48, No. 12

nergy Comparison RMSD max. dev. = n 1 = n i= 1 max ( ') i 2 ( ' ) i i i Journal of Medicinal Chemistry, 2005, Vol. 48, No. 12

Journal of Medicinal Chemistry, 2005, Vol. 48, No. 12 calculated vs. experimental of 12 Roche p38 MAP kinase inhibitors. MM-PBSA using the MAB* force field (filled circles) with FlexX/ScreenScore (empty triangles) Dashed lines at pic50 = 6.0 indicate a threshold of IC50 = 1 µm.

Predicting Correct Binding Modes Illustration of handling of solvation effects. (a) Binding mode suggested by FRD/ChemScore (Rank 7); corresponding MM-PBSA result (Rank 122, ΔGbind ) +7.8 kcal/mol). (b) X-ray binding mode obtained by rotation around the pyrimidine imidazole bond (MM-PBSA: Rank 57, ΔGbind = -2.6 kcal/mol). R = CH2-phenyl. Journal of Medicinal Chemistry, 2005, Vol. 48, No. 12

The enrichment curves show the percentage of inhibitors retrieved as a function of the percentage of total molecules in the database. random selection (black, dashed) ideal performance (black, solid) FRD/ChemScore ranking (red) MM-RDIL ranking with MAB* force field (orange) MM-PBSA ranking with MAB* force field (blue) MM-PBSA ranking with GAFF force field (cyan). Ranking of p38 MAP kinase inhibitors with correct binding mode (N = 11). The diagrams show the ranking obtained with FRD/ChemScore (left) and MM-PBSA (right). Journal of Medicinal Chemistry, 2005, Vol. 48, No. 12

Assessment of multipose MM-PBSA. random selection (black, dashed) ideal performance (black,solid) FRD/ChemScore ranking (red) MM-PBSA (MAB*) ranking using the top scored docking pose (blue) MMPBSA (MAB*) ranking using the three highest scored docking poses (magenta) Comparison of MM-PBSA vs MD-PBSA performance for five different proteins. random selection (black, dashed) ideal performance (black, solid) FRD/Chem-Score ranking (red), MM-PBSA (MAB*) ranking (blue), MDPBSA ranking with the MAB force field (green) MD-PBSA ranking with GAFF (light green) Journal of Medicinal Chemistry, 2005, Vol. 48, No. 12

Lead Optimization \ De Novo Design Superimposed pairs of modeled COX-2 ligands (cyan) and molecules designed by Skelgen (magenta). 2D representations of the general inhibitor topologies are displayed in black. Numbers inside the rings indicate that active ligands with alternative ring sizes are known. The MM-PBSA ranking of the Skelgen structures are: (a) 2, (b) 3, (c) 5, (d)11. Journal of Medicinal Chemistry, 2005, Vol. 48, No. 12

Findings of the Paper MM-PBSA on a single structure: post docking filter which enrich virtual screening results tool to rank de novo design solutions distinguisher between strong and weak binders ΔpIC50 2-3 not small free energy differences MD-PBSA did not improve ranking Journal of Medicinal Chemistry, 2005, Vol. 48, No. 12